Literature DB >> 28704228

Patient attitudes to clozapine initiation.

Siobhan H Gee1, Sukhwinder S Shergill, David M Taylor.   

Abstract

Clozapine is widely underused. No study has assessed views of patients suitable for, but not yet receiving, clozapine. We aimed to assess views of clozapine in patients eligible for clozapine but not yet prescribed it by conducting semistructured interviews with acutely unwell hospital in-patients. We interviewed 61 of 116 eligible patients and 50 (82%) answered all questions. At interview, 33 (54%) of 61 participants had heard of clozapine and 17 (30%) of 57 participants said they would take it if asked. Overall, 31 (57%) of 54 respondents said blood testing would not preclude them taking clozapine. The necessity for hospital admission was seen as the greatest barrier to receiving clozapine - 25 (49%) of 51 respondents stated this would be a reason for their refusing clozapine. Concerns about adverse effects of clozapine were considered sufficient to refuse clozapine in 23 (43.4%) of 53 respondents. Overall, 12 (24%) of 50 respondents felt that clozapine would be helpful to them. Patients' acceptance of clozapine is likely to be improved by offering the opportunity to start clozapine at home and by improved education about the therapeutic benefits of clozapine and the management of its adverse effects. Blood testing does not appear to be an important barrier to the initiation of clozapine.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28704228     DOI: 10.1097/YIC.0000000000000188

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  7 in total

1.  Medication Gaps and Antipsychotic Polypharmacy in Previously Hospitalized Schizophrenia Patients: An Electronic Cohort Study in Three Canadian Provinces.

Authors:  Evyn Peters; Arash Shamloo; Rohit J Lodhi; Gene Marcoux; Kylie Jackson; Shawn Halayka; Lloyd Balbuena
Journal:  Front Psychiatry       Date:  2022-06-15       Impact factor: 5.435

2.  Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals.

Authors:  R J Flanagan; J Lally; S Gee; R Lyon; S Every-Palmer
Journal:  Br Med Bull       Date:  2020-10-14       Impact factor: 4.291

3.  Using a fingerstick test for haematological monitoring in patients treated with clozapine.

Authors:  Matthew Atkins; Philip McGuire; Bhirundra Balgobin; Pravinkumar Patel; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2021-03-25

4.  Cluster Analysis of Clozapine Consumer Perspectives and Comparison to Consumers on Other Antipsychotics.

Authors:  Sumeet Sharma; Sarah L Kopelovich; A Umair Janjua; Cristina Pritchett; Beth Broussard; Meena Dhir; Joseph G Wilson; David R Goldsmith; Robert O Cotes
Journal:  Schizophr Bull Open       Date:  2021-09-28

Review 5.  A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology.

Authors:  Jose de Leon; Can-Jun Ruan; Georgios Schoretsanitis; Carlos De Las Cuevas
Journal:  Psychother Psychosom       Date:  2020-04-14       Impact factor: 17.659

6.  One-Year Outcome and Adherence to Pharmacological Guidelines in First-Episode Schizophrenia: Results From a Consecutive Cohort Study.

Authors:  Petros Drosos; Kolbjørn Brønnick; Inge Joa; Jan Olav Johannessen; Erik Johnsen; Rune Andreas Kroken; Helen Joy Stain; Wenche Ten Velden Hegelstad; Tor Ketil Larsen
Journal:  J Clin Psychopharmacol       Date:  2020 Nov/Dec       Impact factor: 3.118

7.  Prevalence of treatment resistance and clozapine use in early intervention services.

Authors:  Imogen Stokes; Siân Lowri Griffiths; Rowena Jones; Linda Everard; Peter B Jones; David Fowler; Joanne Hodgekins; Tim Amos; Nick Freemantle; Vimal Sharma; Max Marshall; Swaran P Singh; Max Birchwood; Rachel Upthegrove
Journal:  BJPsych Open       Date:  2020-09-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.